ATP6AP1: A Potential Drug Target and Biomarker (G537)

Target Name: ATP6AP1

NCBI ID: G537

ATP6AP1: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the process of muscle contraction and relaxation. It is a nucleotide base that is synthesized from adenosine and phosphate groups. ATP is known for its role in the transfer of energy in cells, and it is often used as a drug target in the treatment of various diseases. One of the most promising ATP-related drug targets is ATP6AP1, a gene that has been identified as a potential drug target in the treatment of various diseases, including cancer.

ATP6AP1 is a gene that encodes a protein known as ATP-activated protein 1 (AP1). This protein is involved in the regulation of various cellular processes, including cell signaling, DNA replication, and protein synthesis. It is known for its role in the transfer of ATP energy to various cellular processes and is a crucial factor in the regulation of muscle contraction and relaxation.

ATP6AP1 has been identified as a potential drug target for various diseases, including cancer. Studies have shown that the expression of ATP6AP1 is often reduced in cancer cells, and that inhibiting its expression may be an effective way to treat cancer. One of the most promising strategies for the treatment of cancer is the use of small molecules that can inhibit the activity of ATP6AP1. These small molecules, known as inhibitors, can be used to reduce the amount of ATP6AP1 produced in cancer cells, leading to a reduction in the growth and spread of the cancer.

In addition to its potential as a drug target, ATP6AP1 has also been identified as a potential biomarker for the diagnosis and monitoring of various diseases. The expression of ATP6AP1 has been shown to be reduced in a variety of diseases, including cancer, neurodegenerative diseases, and respiratory disorders. This suggests that ATP6AP1 may be a useful biomarker for the diagnosis and monitoring of these diseases.

The identification of ATP6AP1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. The use of small molecules that can inhibit the activity of ATP6AP1 may be an effective way to treat cancer and other diseases. Additionally, the use of ATP6AP1 as a biomarker may be an effective way to diagnose and monitor the progress of these diseases. Further research is needed to fully understand the potential of ATP6AP1 as a drug target and biomarker, and to develop effective treatments for the treatment of various diseases.

Protein Name: ATPase H+ Transporting Accessory Protein 1

Functions: Accessory subunit of the proton-transporting vacuolar (V)-ATPase protein pump, which is required for luminal acidification of secretory vesicles (PubMed:33065002). Guides the V-type ATPase into specialized subcellular compartments, such as neuroendocrine regulated secretory vesicles or the ruffled border of the osteoclast, thereby regulating its activity (PubMed:27231034). Involved in membrane trafficking and Ca(2+)-dependent membrane fusion (PubMed:27231034). May play a role in the assembly of the V-type ATPase complex (Probable). In aerobic conditions, involved in intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation (PubMed:28296633). In islets of Langerhans cells, may regulate the acidification of dense-core secretory granules (By similarity)

More Common Targets